Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Novartis hopes Kymriah acceleration can save its CAR
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
No price relief in 2019, Pfizer confirms
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
Big caps provide a safe haven
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
